Respiratory syncytial virus remains the leading cause of infant hospitalization in the United States, yet no antiviral treatment exists for those already infected. A new laboratory study suggests that indomethacin, an inexpensive arthritis drug with decades of clinical history, may interfere with RSV's ability to replicate inside human respiratory cells — a finding that, while preliminary, opens a door long considered closed. Science moves carefully from petri dish to patient, and experts remind us that promising beginnings do not always become cures, but in a disease without treatment options
Arthritis drug shows RSV-fighting potential in lab study, but clinical use remains distant
RSV is the leading cause of infant hospitalization in the U.S., with babies under 6 months and adults over 65 at highest risk of severe disease and death.
What happens in a lab can differ dramatically from what occurs in living patients
Mark
Why does this matter if it's just a lab study? Don't we already have vaccines?
Mimi
The vaccines are preventive—they work before infection. But once someone has RSV, there's nothing to treat it with. That's the gap. For infants and elderly people, that gap can be life-threatening.
Mark
So indomethacin could fill that gap?
Mimi
It might. The lab work shows it can slow the virus down once it's inside cells. But that's a long way from proving it works in actual patients. The body is messier than a petri dish.
Mark
Why did aspirin fail when it works the same way as indomethacin?
Mimi
That's the mystery. It suggests indomethacin's antiviral effect isn't about pain relief at all—it's something else about how the drug interacts with RSV specifically. They don't fully understand it yet.
Mark
Is indomethacin safe enough to try in people?
Mimi
It has a track record. Premature babies already receive it intravenously for heart problems. Short-term use is generally safe. But longer treatment or higher doses can damage kidneys and cause bleeding. That's a real constraint.
Mark
What happens next?
Mimi
Clinical trials. Someone has to test whether what worked in cells actually works in infected patients. That takes years and money. Until then, this is a promising lead, not a treatment.
Der Puls
- RSV hospitalizes more American infants than any other infection, yet once a patient is infected, doctors have no approved antiviral drug to offer — only supportive care.
- A May 2026 laboratory study found that indomethacin, a cheap and widely available painkiller, significantly reduced RSV's ability to replicate in human larynx, bronchus, and lung cells at low, cell-safe doses.
- The drug's timing matters critically — it only worked after the virus had already entered cells, and had no effect when given before infection or during initial attachment, a constraint that will shape any future treatment strategy.
- Indomethacin has shown antiviral activity against herpesvirus, rotavirus, SARS, and COVID-19 in prior research, and already has a safety record in premature newborns, giving researchers a meaningful head start toward clinical trials.
- Infectious disease specialists welcome the findings as a legitimate first step but are clear: laboratory results do not change how RSV patients are treated today, and human trials are needed before any clinical conclusions can be drawn.
Respiratory syncytial virus remains the leading cause of infant hospitalization in the United States, yet no antiviral treatment exists for those already infected. A new laboratory study suggests that indomethacin, an inexpensive arthritis drug with decades of clinical history, may interfere with RSV's ability to replicate inside human respiratory cells — a finding that, while preliminary, opens a door long considered closed. Science moves carefully from petri dish to patient, and experts remind us that promising beginnings do not always become cures, but in a disease without treatment options, even early light is worth following.
Respiratory syncytial virus sends more American infants to the hospital than any other infection, striking hardest at babies under six months and adults over sixty-five. Despite this burden, no antiviral drug exists for infected patients — only preventive vaccines and antibody treatments for children at risk. A laboratory study published in May in the journal Virus Research suggests that an old arthritis medication, indomethacin, might one day fill that gap.
Researchers infected human cells from the larynx, bronchus, and lungs with RSV, then treated them with indomethacin at varying doses. The drug interfered with a protein the virus needs to invade and replicate within cells, producing a significant reduction in viral copying at low doses — without harming the healthy cells themselves. Notably, aspirin, which shares indomethacin's pain-relief mechanism, had no effect on RSV at all, suggesting the antiviral action is something distinct.
The drug's limits are real: it only worked after the virus had already entered cells, not before or during initial attachment. Still, indomethacin has previously shown antiviral activity against herpesvirus, rotavirus, and the coronaviruses behind SARS and COVID-19. In one small COVID-19 trial, patients given indomethacin recovered roughly twice as fast as those taking acetaminophen.
Experts not involved in the study urged caution. Dr. Amy Edwards, a pediatric infectious disease physician in Ohio, noted that laboratory findings frequently behave differently in living patients, and that early-stage research identifies candidates for trials — it does not justify clinical use. Dr. Aaron Glatt of Mount Sinai South Nassau agreed the findings were interesting but said they would not change how doctors manage RSV in the near term.
One encouraging detail: indomethacin is already used intravenously in premature infants to treat a heart condition, giving it an established pediatric safety profile. Higher doses and prolonged use carry risks including kidney problems, but short-term use is generally well tolerated. Researchers say the next steps are understanding the precise mechanism behind the drug's antiviral effect and moving toward human clinical trials — the long road that still separates a promising laboratory result from a treatment that can help a sick child.
Respiratory syncytial virus sends more infants to American hospitals than any other infection. Babies under six months old face the steepest risk of severe disease and death. Adults over sixty-five are vulnerable too. Yet despite the burden, there is no antiviral drug available once someone is infected—only vaccines for prevention and antibody treatments for children. A laboratory study published in May suggests an old, inexpensive arthritis medication might change that picture, though experts are careful to temper expectations.
The drug is indomethacin, a nonsteroidal anti-inflammatory painkiller long used to treat arthritis and other conditions. In the new research, published in the journal Virus Research, scientists found that indomethacin interferes with a protein RSV needs to invade human cells and replicate. When researchers infected cells from the larynx, bronchus, and lungs with the virus and then treated them with indomethacin at various doses, the drug significantly reduced the virus's ability to copy itself. Crucially, it did this at very low doses without damaging the healthy cells themselves.
But the drug only worked after the virus had already entered the cells. Administering it beforehand, or during the narrow window when the virus first attached to cell surfaces, produced no antiviral effect. The researchers also tested aspirin, which operates through a similar pain-relief mechanism as indomethacin. Aspirin had no effect on RSV whatsoever, suggesting that indomethacin's antiviral power is distinct from its anti-inflammatory properties.
The finding is intriguing because indomethacin has shown antiviral activity against other viruses in previous laboratory and clinical work—herpesvirus, rotavirus, and the coronaviruses responsible for SARS and COVID-19. In one small clinical trial, COVID-19 patients given indomethacin recovered faster than those taking acetaminophen, with most symptoms clearing in half the time. Yet despite this track record, the drug has never been approved as an antiviral treatment for any infection.
Dr. Amy Edwards, a pediatric infectious disease physician at University Hospitals in Ohio who was not involved in the study, offered a measured perspective. What happens in a laboratory can differ dramatically from what occurs in living patients, she explained. Early-stage studies like this one serve as important first steps toward identifying which treatments might warrant clinical trials, but they do not justify immediate use in patient care. Dr. Aaron Glatt, chief of infectious diseases at Mount Sinai South Nassau in New York, echoed the caution. The findings are interesting, he said, but they will not alter how doctors treat RSV patients in the near term.
Indomethacin already has a foothold in pediatric medicine. It is used intravenously in premature infants to treat patent ductus arteriosus, a heart condition in which a blood vessel fails to close after birth. Edwards noted that this long history of relatively safe use in newborns is noteworthy. For short-term treatment, indomethacin is generally well tolerated. However, higher doses and prolonged use carry risks—kidney problems and bloody stool among them.
The researchers acknowledge that much work remains. They need to understand the precise mechanism by which indomethacin stops the virus from multiplying and spreading. They need to determine whether the drug actually benefits people infected with RSV. And they need to move from petri dishes to human trials. Until then, indomethacin remains what it has always been: a painkiller with an intriguing but unproven potential against a virus that still has no specific cure.
Bemerkenswerte Zitate
Laboratory findings don't always translate into real-world results, and early studies are important first steps toward identifying treatments for clinical trials but do not justify immediate patient use.— Dr. Amy Edwards, pediatric infectious disease physician, University Hospitals Ohio
The findings are interesting but will not change how doctors treat RSV patients in the short term.— Dr. Aaron Glatt, chief of infectious diseases, Mount Sinai South Nassau
Möchten Sie die ganze Geschichte?
Das Original lesen bei Livescience.com ↗
Health & Medicine